Page 1580 - Small Animal Internal Medicine, 6th Edition

1552 Index

Cat scratch disease, 1540 Central venous pressure (CVP) Chemotherapy (Continued) Cholestyramine, 913–914
Cataracts acute kidney injury, 690 complications of, 1276–1287 Chondroitin sulfate, 1196, 1197t,
diabetes mellitus as cause of, 809–810, in constrictive pericardial disease, 185 acute tumor lysis syndrome, 1286, Chondroprotective agents, 1196, 1197t,
1209t–1210t
VetBooks.ir Cathartics, 443–446, 445t, 1100b measurement of, 52 alopecia, 1282–1283, 1283f Chondrosarcomas, 1260–1261
1286f
heart failure and, 65
810f, 828–829
in dogs, 809–810, 810f, 828–829
1207
overhydration assessments, 433
anemia, 1278
pericardial effusion levels of, 181
Catheters
cardiotoxicity, 1283–1284
Chorioretinitis, 242f, 1488
nasal, 383–384, 384f Central vestibular disease anorexia, 1281 Chordae tendineae rupture, 124f, 130
for thoracocentesis, 367 cerebrovascular disease causing, dermatologic toxicity, 1282–1283, punctate, 1522f
transtracheal, 383t, 384 1115–1116 1282f Chronic airway disease, 131
Cauda equina compression, 1054 clinical findings of, 1110b feline susceptibility to, 1276 Chronic bronchitis, canine, 324–328,
Cauda equina syndrome, 1149–1151, disorders that cause, 1115–1116 gastroenterocolitis, 1281 330b
1149f–1151f inflammatory diseases causing, 1115 gastrointestinal toxicity, 1280–1281 antibiotics for, 328
Caudal agenesis, 1155 intracranial neoplasms causing, 1115 general considerations, 1276 breeds commonly affected, 324
Caudal aortic thromboembolism, lesion localization, 1110–1111 hematologic toxicity, 1276–1280 client communication challenges
1162–1163 thiamine deficiency causing, 1115 hepatotoxicity, 1285 associated with, 321
Caudal nasopharynx, evaluation of, 276 Centrine. see Aminopentamide hypersensitivity reactions, 1281 clinical features of, 322, 324–325
Caudal stomatitis, 1439f Centronuclear myopathy, 1179–1180, myelosuppression, 1280 complications of, 325, 328
Caudal vena cava, 17 1180f nausea, 1280 cough suppressants for, 323, 323t
Caudate cells, 666–667 Cephalexin, 386t–388t, 1185t–1186t nephrotoxicity, 1284 diagnosis of, 322–323
Caval syndrome bacterial infections treated with, neurotoxicity, 1285 doxycycline for, 328
clinicopathologic findings, 202 1437t–1438t neutropenia, 1278, 1279f drug therapies for, 327–328, 327b
deaths caused by, 202 joint disease treated with, 1209t–1210t pancreatitis, 1283 etiology of, 321–322, 322b, 324
description of, 196 Cephalosporins. see also specific drug pulmonary toxicity, 1285–1286 exacerbating factors, 326
heartworm disease as cause of, bacterial meningoencephalomyelitis sterile hemorrhagic cystitis, 1284 prevention of, 323–324
202–203 treated with, 1123–1124 thrombocytopenia, 1278 prognosis for, 323, 328
signs of, 202 diskospondylitis treated with, 1144 urotoxicity, 1284–1285 treatment of, 323, 323t, 326
Cavalier King Charles Spaniels, 1395 infective endocarditis treated with, vomiting, 1280 uncomplicated, 323
episodic falling in, 1106 136–137 contraindications for, 1272 vaccines, 324
Cavitary lesions, 294, 295f types of, 1437t–1438t dosage calculations, 1271 Chronic enteropathy, 493–495
Cefadroxil, 1437t–1438t Cephulac. see Lactulose feline leukemia virus-associated Chronic gastritis, 463–464
Cefazolin, 386t–388t, 515t–517t, Cerebellar ataxia, 1046b neoplasia treated with, 1497 Chronic heart failure, 127b. see also
1437t–1438t Cerebellar cortical degeneration, hematologic monitoring during, 1279 Congestive heart failure; Heart
Cefotaxime, 1185t–1186t, 1209t–1210t, 1080–1081 indications for, 1272 failure
1437t–1438t Cerebellomedullary angle, 1111 local tissue reactions, 1283b amlodipine for, 71
Cefovecin, 1437t–1438t Cerebellomedullary cistern, 1070f lymphoma treated with, 1302 angiotensin-converting enzyme
Cefoxitin, 515t–517t, 1437t–1438t Cerebellum metronomic, 1273–1274 inhibitors for, 67–68
Cefpodoxime, 1437t–1438t anatomy of, 1038–1039 nasal tumors treated with, 265 benazepril for, 68
Ceftiofur, 1437t–1438t lesions of, 1038b osteosarcoma treated with, 1327, captopril for, 64t, 68
Ceftriaxone, 1185t–1186t, 1209t–1210t Cerebral cortex, 1037 1327b client education about, 73–74
Cell cycle, 1269, 1270f Cerebral meningiomas, 1081 principles of, 1270–1271 dietary considerations for, 72–73
Cell-mediated immunity, 1451 Cerebrospinal fluid protocols for, 1337b–1339b digoxin for, 69–70
Cellulitis, 979f analysis of, 1071, 1072b toxicities associated with, 1277t–1278t diuretics for, 66–67
Central cord syndrome, 1041 bacterial meningoencephalomyelitis tumor kinetics, 1269–1275, 1270f drug therapy for, 64t
Central diabetes insipidus, 654t–655t, findings, 1123 Chest, auscultation for, 7–8, 8f enalapril for, 68
742, 742b, 1033 canine distemper virus findings, 1486 Chest tubes furosemide for, 64t, 66, 128
Central nervous system collection of placement of, 367–369, 368f–369f general considerations for, 66
brain. see Brain at cerebellomedullary cistern, 1070f pneumothorax complications, 367 hydralazine for, 71
feline infectious peritonitis, nonseptic cisternal puncture for, 1069–1070, thoracic radiographs of, 369 hyponatremia in, 74
exudate and, 363 1070f Cheyletiella spp., 1430 loop diuretics for, 66–67
infections of, 1440t, 1442 contraindications for, 1068–1069 Chief cells, 758 monitoring of, 73–74, 74b
inflammation of, 1117 indications for, 1067–1068 Chinese Shar-Peis nitrates for, 71–72
lymphoma of, 1081, 1307–1309, 1308f lumbar puncture for, 1070, 1071f enteropathy in, 497 pimobendan for, 69, 128
spinal cord. see Spinal cord technique for, 1069–1070 familial fever in, 1205, 1245t prazosin for, 71
Central nervous system diseases granulomatous meningoencephalitis glomerular disease in, 680 reevaluations, 73–74
ancillary tests for, 1118t findings, 1120–1121 granulomatous meningoencephalitis refractory, 74–75, 127b, 129–130
bacterial meningoencephalomyelitis, protein concentration in, 1071 in, 1120f salt restriction for, 72, 128–129
1123–1124 syringomyelia, 1155 Chitosan, 913 spironolactone for, 67
canine distemper virus, 1124–1125 white blood cells in, 1071 Chlamydia felis, 1453, 1533t–1535t, 1542 thiazide diuretics for, 67
canine eosinophilic meningitis/ Cerenia. see Maropitant Chlamydophila spp. Chronic hepatitis, canine, 584–598
meningoencephalitis, 1122 Cervical disk extrusion, 1136, 1138t, C. felis, 1427 antibiotics for, 593
canine steroid-responsive tremor 1139 infection caused by, 258 antifibrotics for, 593
syndrome, 1122 Cervical intumescence, 1039, 1039f, Chlorambucil, 442, 515t–517t antioxidants for, 590–591
diagnosis of, 1117 1041b dosage of, 1225t breed and, 585b
feline immunodeficiency virus Cervical spondylomyelopathy, immune-mediated diseases treated choleretics for, 590
encephalopathy, 1123 1151–1153, 1152f–1153f with, 1224, 1225t, 1255t–1256t clinical features of, 588–589, 589f
feline infectious peritonitis Cervical trachea, 287 immune-mediated polyarthritis diagnosis of, 589
ancillary tests for, 1118t Cervical ultrasound, 794, 795f treated with, 1204t diet for, 590, 591t
signs of, 1126 Cesarean section, 972–974, 974f joint disease treated with, 1209t–1210t drugs for, 590–595
feline polioencephalitis, 1122–1123 Cestex. see Epsiprantel Chloramphenicol, 386t–388t, glucocorticoids for, 592, 592f
granulomatous meningoencephalitis, Cestodes, 1537 1437t–1438t, 1479 idiopathic, 586–595
1087–1088, 1120–1121, 1121b Cetirizine, 386t–388t Chlorinated hydrocarbons, 1099b immune-mediated, 587
infectious, 1123–1129 Chagas disease, 153–154 Chlorothiazide, 64t, 67, 896t–897t immunosuppressive drugs for,
Lyme disease, 1128 Chédiak-Higashi syndrome, 1372 Chlorpheniramine, 266, 386t–388t 592–593
mycotic infections, 1128 Chemodectomas, 176, 185 Chlorpromazine, 438t, 1185t–1186t lobular dissecting, 587
neck pain associated with, 1117–1119 Chemotherapy, 1269–1275. see also Chlorpropamide, 896t–897t shared pathogenesis of, 588
necrotizing leukoencephalitis, 1122 Anticancer drugs Cholangitis, 567–573, 599–600 toxic causes of, 587–588
necrotizing meningoencephalomyelitis, acute leukemia treated with, 1317b chronic neutrophilic, 568t treatment of, 589–595
1121–1122 body weight conversions to body liver fluke infestation and, 568t, Chronic idiopathic polyneuropathy,
neosporosis, 1118t, 1127–1128, 1127f surface area, 1271, 1271t 572–573, 573b 1165–1166
noninfectious, 1119–1123 brain tumors treated with, 1082 lymphocytic, 570–572, 571f Chronic inflammatory demyelinating
rabies, 1125–1126 canine thyroid neoplasia treated with, neutrophilic, 568t, 569f polyneuropathy (CIDP), 1165, 1166f
rickettsial diseases, 1128–1129 803 sclerosing, 572 Chronic kidney disease (CKD), 692–702
steroid-responsive meningitis-arteritis, cell kinetics, 1269, 1270f Cholecystitis, 569, 573, 599–600 acid-base balance, 697
1118f, 1119, 1119b chronic leukemia treated with, 1319b Choleliths, 573 acute kidney injury versus, 687t
toxoplasmosis, 1126 combination, 1270–1271 Choleretics, 590 anemia in, 697